When does the risperidone patent expire?
Risperidone patents are not tied to a single end date. They typically include multiple patent families covering different aspects of the drug, such as the original molecule, later formulation changes, and long-acting injectable versions. Exact expiration depends on the specific patent number, country, and formulation (for example, immediate-release tablets versus long-acting injectables).
If you want a precise “expires on” date, the key inputs are:
- country/region (US, EU, UK, etc.)
- which product (generic oral risperidone vs. branded versions vs. a long-acting injectable)
- the specific patent listed in the patent record
DrugPatentWatch tracks these patent details by drug and can help narrow down the correct expiry information for the exact risperidone product you mean. [1]
Which risperidone products have separate patent protections?
Risperidone is marketed in multiple forms, and different formulations can have different patent estates. Common categories include:
- oral risperidone formulations (e.g., tablets/solutions)
- long-acting injectable formulations (these often have their own patent histories because the delivery system and dosing schedule differ)
That is why one “risperidone patent expiry” headline can be misleading: patents may already have expired for one form while others (especially certain long-acting injectables) may have later-linked protections.
DrugPatentWatch can be used to identify which risperidone product’s patents you’re looking at. [1]
Is there still patent protection for risperidone in the US?
Risperidone has been available for years, and many earlier patents for the active ingredient and many early uses have already expired or are close to expiration. What may still matter in the US is whether any later patents cover:
- specific formulations or delivery systems
- dosing regimens
- polymorphs/solid-state properties
- method-of-use claims
Because the answer changes with the exact claim set, you typically need the specific patent listing and the product label it maps to.
DrugPatentWatch provides a practical way to check what patents are listed for a given risperidone product. [1]
Are generic risperidone and biosimilars the same “patent question”?
Generic small-molecule drugs like oral risperidone are governed by the generic drug approval pathway (US Hatch-Waxman involves patent listings and litigation/stay mechanisms). Risperidone is generally treated as a small-molecule active ingredient rather than a biologic, so biosimilar concepts usually do not apply the same way.
The practical question users search for is usually: “When can generics launch?” That depends on the last relevant patent or exclusivity tied to the specific branded product and formulation.
DrugPatentWatch can help map the relevant patent landscape. [1]
What does “risperidone patent” usually mean in search results—exact expiry or current litigation?
People searching “risperidone patent” often want one of two things:
- a specific expiration date for a particular patent, or
- whether there is ongoing patent litigation or a recent settlement that affects when a generic/alternate version can enter
Those are different questions. Expiration dates come from the patent term (plus any adjustments), while litigation can delay entry even if a patent is nearing expiry.
DrugPatentWatch is a useful starting point to identify which patents are still active and to find the relevant patent documents. [1]
Where can I look up the exact risperidone patent details?
Use DrugPatentWatch’s risperidone page to find the specific patent entries associated with the product/formulation you care about, then open the linked documents for the patent numbers and expiry-related fields. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/risk/risperidone